US 2018/0022751 A1 · N-SUBSTITUTED 8-[(2,6-DIFLUOROBENZYL)OXY]-2,6-DIMETHYLIMIDAZO[1,2-A]PYRAZIN-3-CARBOXAMIDE DERIVATIVES AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) FOR THE TREATMENT OF CARDIOVASCULAR DISEASES

Abstract

The present application relates to novel substituted imidazo[1,2-a]pyrazine carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Claims22

Dependent claims

Compound of the formula (I)

in which
R1 represents a group of the formula
where
* represents the point of attachment to the nitrogen atom,
and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides and salts thereof.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

15/548,310Filed 2 Feb 2016

Priority

EP 15153959.05 Feb 2015

Published

25 Jan 2018

Term ends

Not estimatedThe source records don’t support an estimate.

Classification23 codes

C07D 487/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61K 31/4985
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: pyrazines or piperazines…
A61K 31/695
Medicinal preparations containing organic active ingredients: silicon compounds
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…

N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (sgc) for the treatment of cardiovascular diseases

Life of this patent

N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (sgc) for the treatment of cardiovascular diseases

Life of this patent

Abstract

Claims22